A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

NCT00796757 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Cancer

Interventions

DRUG: bevacizumab [Avastin]
DRUG: interferon alfa-2a

Sponsor

Hoffmann-La Roche